RAD51B and leukemia: We then show that the HR pathway component RAD51B and its associated expression signature are a hallmark of chemotherapeutic response in hypodiploid leukemia using single-cell profiling of leukemia cells in a patient-derived xenograft (PDX) model of near-haploid B-ALL, and further confirmed such a signature in childhood hypodiploid B-ALL patient samples.